Vertex Pharmaceuticals Financial Ratios
VRTX / Health Care|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
21.2%
ROE ranks in the above average among Health Care companies
Profit Margin
32.9%
Net Income / Revenue
Asset Turnover
0.47
Revenue / Total Assets
Equity Multiplier
1.37
Total Assets / Equity
Composite: 21.2% (reported: 21.2%)
Profitability
Liquidity
Current Ratio
2.90
Quick Ratio
2.46
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.47
Inventory Turnover
0.98
Days Sales Outstanding
62 days
As of FY2025 · SEC 10-K · Updated Mar 17, 2026
Earnings Quality
Accrual Ratio
+1.3%
+1.5pp YoY
Earnings are roughly in line with operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.